SCLC is sensitive to THZ1, a covalent CDK7 inhibitor with single-agent activity in T-cell acute lymphoblastic leukemia, MYCN- dependent neuroblastoma, and triple-negative breast cancer137,138. The gene discussed is CDK7; the disease is T-cell acute lymphoblastic leukemia.